The competitive landscape in surgical robotics changed materially in the first quarter of 2026. Johnson & Johnson submitted a new robotic system to the FDA. CMR Surgical made its formal U.S. debut. Medtronic followed an earlier clearance with plans to expand into new procedure categories. For founders building surgical devices or adjacent enabling technology, the procurement environment that hospitals are operating in looks different today than it did eighteen months ago.
J&J Submits Ottava for FDA De Novo Classification
In January 2026, Johnson & Johnson MedTech submitted the Ottava robotic surgical system for FDA de novo classification, targeting soft tissue procedures in the upper abdomen, including gastric bypass, sleeve gastrectomy, small bowel resection, and hiatal hernia repair. The submission is supported by data from an investigational device exemption study, with a separate IDE approval received in late 2025 for inguinal hernia trials, according to reporting from MedTech Dive.
The submission puts two of the world's largest medical device companies in active FDA review simultaneously. J&J and Medtronic are both competing for soft tissue robotic procedure volume that Intuitive Surgical has held almost entirely for the past decade.
CMR Surgical Formally Enters the U.S. Market
In late March 2026, CMR Surgical introduced its Versius robotic system to U.S. surgeons at the Society of American Gastrointestinal and Endoscopic Surgeons meeting in Tampa. CMR reports more than 45,000 patients worldwide have been treated on Versius robots across 30-plus countries. The company received 510(k) clearance in December 2025 for its next-generation Versius Plus system in gallbladder removal, as reported by MedTech Dive.
CMR is positioning Versius as complementary to existing platforms rather than a direct replacement decision. CEO Massimiliano Colella has described the approach as fitting into what hospitals already have in place. For hospitals that have resisted robotics investment due to capital or commitment concerns, a modular, lower-disruption platform changes the evaluation calculus.
Medtronic's Hugo Expands Beyond Urology
Medtronic received FDA clearance for its Hugo robotic system in urology in December 2025 and is now pursuing expansion into general surgery and gynecology. The initial U.S. launch is concentrated at select leading institutions, with broader rollout planned as clinical evidence accumulates, according to MedTech Dive. Industry analysts expect meaningful but limited market impact through 2027.
A robotic platform that justifies capital across three clinical departments is a materially different procurement conversation than a single-indication system. Medtronic's multi-specialty ambition changes the return-on-investment calculation for hospital procurement teams, and it changes the competitive surface area that all adjacent technologies have to navigate.
Intuitive Adds Cardiac Indications, Projects Slower Growth
Intuitive Surgical received FDA clearance for nine cardiac surgical indications, including mitral valve repair and left atrial appendage closure, and is beginning a limited U.S. rollout with specialized training programs. The company projects worldwide da Vinci procedure growth of 13 to 15 percent in 2026, below last year's approximately 18 percent growth rate, according to MedTech Dive.
The slower growth projection reflects the base effect of a large installed base and the time it takes for new procedure indications to translate into volume. For founders building cardiac-adjacent enabling technology, the clearance signals where Intuitive sees its next growth frontier.
New Entrants Target the Uncontested Hospital Segment
A set of smaller developers including Distalmotion, Moon Surgical, and Virtual Incision are pursuing ambulatory surgery centers and hospitals that have never operated a robotic surgery program, according to MedTech Dive analysis. These institutions represent the market segment where Intuitive has the least penetration and where capital constraints are most acute.
Two tiers are emerging in robotic surgery: large multinationals competing for established hospital accounts, and purpose-built platforms targeting greenfield institutions. The implications for how you position enabling technology, instruments, or software differ materially depending on which tier your device is built for.
Dave's take
What I watch most closely in this shift is not the competitive dynamics themselves but what they are doing to the hospital procurement process. Buyers who spent the last decade with a single option are now running genuine platform evaluations, and that changes the evidence requirements, the sales cycle, and the risk calculus for everything that touches the robotic workflow. If your product depends on hospital adoption of a specific platform, you need a clear thesis on which platform wins in your target accounts, and why.
I'm here to help you scale.
Work With Dave